Ireland

Ireland is a small but increasingly credible psychedelic research country, while remaining clinically restrictive for classical psychedelics. LSD, mescaline, DMT and psilocin are Schedule 1 controlled drugs, and fungi containing psilocin or an ester of psilocin have been controlled since 2006.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Ireland.

1
Ireland is research-permissive but clinically restrictive for classical psychedelics.
2
Spravato changes the access picture for depression, but it does not create broader psychedelic access.
3
Ketamine is Schedule 3 and medically usable, while depression use is mainly visible through research rather than a standard national access service.
4
Dublin and Tallaght form the main psychedelic research hub, anchored by Trinity, Tallaght services, St James's and St Patrick's collaborators.
5
Galway now has a meaningful signal through CYB003 EMBRACE site activity and esketamine-service discussion.
6
Near-term change is more likely to come from trial evidence and commissioning decisions than from statutory liberalisation.

Research Snapshot

Blossom currently tracks 13 psychedelic clinical trials connected to Ireland, including 2 active studies.

Active trials: 2
Total trials: 13
Stakeholders: 6
Events: 0

Top Compounds

Ketamine(6)
Psilocybin(5)
5-MeO-DMT(1)

Active Trial Preview

View all trials →

Medical Access Snapshot

Ireland remains clinically restrictive for classical psychedelics. Schedule 1 substances such as LSD, mescaline, DMT and psilocin are limited to narrow licensed purposes such as research, and psilocin-containing fungi have been controlled since 2006. The clear access route is intranasal esketamine: Spravato is EMA-authorised and HSE reimbursement was approved after price negotiations.

View trials→View stakeholders→Open access guide→

Regulatory Status

Ireland remains tightly controlled for classical psychedelics. Under the Misuse of Drugs framework, Schedule 1 substances include lysergide or LSD, mescaline, DMT and psilocin, and fungi containing psilocin or an ester of psilocin have been expressly controlled since 2006. Schedule 1 substances are unlawful except for narrow licensed purposes such as research. Ketamine is different because it is a Schedule 3 controlled drug and can circulate as a controlled medicinal product under prescription and supply rules. No classical psychedelic medicine is generally authorised for Irish clinical use. Esketamine is the clearest present-day psychiatric access route because Spravato is EMA-authorised and HSE reimbursement was approved after price negotiations.

History of Research in Ireland

Modern Irish control of psychedelics sits within the Misuse of Drugs framework dating back to 1977. The current 2017 instruments keep Schedule 1 substances tightly restricted, with lawful use narrowed to licensed purposes such as research and forensic or specified industrial uses. # #

Ireland specifically closed the fresh mushroom loophole in 2006 by controlling fungi containing psilocin or an ester of psilocin. That is the key legal detail for psilocybin mushrooms and should replace any softer wording about uncertain mushroom status. #

The first modern Irish psychedelic-adjacent clinical activity with a serious footprint came through ketamine research in severe depression. St Patrick's and Trinity built a sequence of studies that gave Ireland practical experience with rapid-acting antidepressant research before the current psilocybin and next-generation pipeline matured. # #

Ireland's classical-psychedelic restart became more visible through COMPASS Pathways and the Trinity-Tallaght research group. Trinity reported Irish participation in the published COMP360 Phase IIb trial at Tallaght University Hospital, and current university pages now list active sponsored and publicly funded projects. # # #

Dublin, Tallaght and Galway

Dublin and Tallaght are the clearest Irish hub. The Trinity College Dublin and Tallaght University Hospital Psychedelic Research Group publicly lists multiple sponsored and publicly funded projects, with trials connected to Tallaght Adult Mental Health Service and the Wellcome-HRB Clinical Research Facility at St James's Hospital. # #

St Patrick's Mental Health Services is the other major Dublin actor, strongest in ketamine and depression research. Its work feeds into the published Irish ketamine evidence base, including the KARMA-Dep 2 result. # #

Galway deserves a larger role than older summaries gave it. Irish NREC documentation names La Nua Day Hospital Mental Health Centre in Galway for CYB003 EMBRACE, and HSE material shows Galway University Hospital presenting on intranasal esketamine for treatment-resistant depression. # #

The main national access institutions are NCPE and HSE for reimbursement and commissioning, while NREC and the Department of Health matter for ethics review and policy direction. Their current public materials support research growth, not general psychedelic access. # # #

Research Focus

Depression is the centre of gravity. Ireland-linked work includes COMP360 psilocybin studies in treatment-resistant depression, the Phase III CYB003 EMBRACE trial in major depressive disorder, GH001 mebufotenin in treatment-resistant depression, and St Patrick's or Trinity ketamine programmes in severe depression. # # # # #

The pipeline is broadening. Public trial sources show a Tallaght site in a COMP360 anorexia nervosa study, while Trinity lists a Transcend PTSD trial, HRB-funded translational work on psychedelic immunology in depression, and POSITRON, a pilot psilocybin feasibility study for cocaine use disorder. # # # #

Evidence maturity is mixed. COMP360 Phase IIb has peer-reviewed data, GH001 Phase IIb has a published 2026 signal, and KARMA-Dep 2 produced a negative ketamine finding in hospitalised depression. CYB003 and several local non-depression projects remain investigational. # # # #

Key Milestones

1977

The Misuse of Drugs Act creates the modern Irish controlled-drugs framework.

31 Jan 2006

Ireland controls fungi containing psilocin or an ester of psilocin, closing the mushroom loophole.

4 May 2017

The 2017 Misuse of Drugs instruments consolidate current Schedule 1 and Schedule 3 positions relevant to psychedelics and ketamine.

Jan 2022

HSE approves reimbursement for Spravato after confidential price negotiations, according to NCPE.

3 Nov 2022

Trinity announces Irish participation in the published COMP360 Phase IIb trial at Tallaght University Hospital.

31 May 2023

Trinity and HRB publicise POSITRON, a psilocybin-with-psychological-support feasibility study for cocaine use disorder.

2024

HRB funds knowledge-translation and translational research work around psychedelic science in Ireland.

21 May 2025

Irish NREC minutes identify Galway and Dublin institutions for the CYB003 EMBRACE Phase III study.

22 Oct 2025

KARMA-Dep 2 reports no added benefit for serial ketamine infusions in hospitalised depression.

5 Feb 2026

Ireland publishes the draft National Drugs Strategy 2026-2030 for consultation, continuing a health-led policy frame without creating psychedelic authorisation.

2026

GH001 Phase IIb data are published, reporting significant improvement versus placebo in treatment-resistant depression.

Future Outlook

The next 12 to 24 months are more likely to change the evidence base than the statute book. CYB003 EMBRACE names Irish institutions in Dublin and Galway, Trinity lists ongoing sponsored and public projects, and GH Research remains an Irish-headquartered sponsor with a published depression signal. # # # #

Patient access is a separate question. The most realistic near-term access development is better commissioning and geographic spread for reimbursed esketamine. Any future Irish access to classical psychedelic medicines would still require evidence, product authorisation, controlled-drug permissions, service protocols, trained teams and a positive reimbursement route. # # # #